Furthermore, patients harboring NPM1 mutation in the absence of DNMT3A mutations obtained a CR rate of 83.3% (5 of 6 cases), which was significantly higher than that of MDS patients without NPM1 mutations. This evidence concerns the gene DNMT3A and myelodysplastic syndrome.